Anti U11 U12 Rnp Antibody Positivity C5676683
Antibody associated with scleroderma and interstitial lung disease. Treatment focuses on managing lung complications and symptoms.
Key facts at a glance
- ICD-10
- D89.9
- ICD-11
- 3A00.0
- Body system
- immunologic
- Severity
- moderate
- Chronic
- true
Signs and symptoms
Common signs and symptoms that may indicate this condition.
Warning signs - seek immediate care
Chest pain
Generalized symptoms
(immunologic)Noticeable symptoms that may vary in intensity over time.
Frequency: Common at all stages
Skin thickening
(skin)Digital ulcers
(skin)Dysphagia
(gastrointestinal)Diagnosis and tests
How this condition is diagnosed and what test results mean.
Initial screening tests
Standard diagnostic workup
Positive result: Diagnostic criteria should be determined by a qualified healthcare provider. [Content pending medical review.]
Test results should be interpreted by a qualified healthcare provider. [Content pending medical review.]
Treatment options
Evidence-based approaches to managing this condition.
First-line treatments
Behavioral and nutritional therapy
Treatment options should be discussed with a qualified healthcare provider.
Interstitial Lung Disease Surveillance
Regular pulmonary function testing and high-resolution CT imaging to detect and monitor lung involvement common with anti-U11-U12 antibodies.
Immunomodulatory Treatment
Corticosteroids and steroid-sparing agents such as mycophenolate mofetil to control autoimmune-mediated tissue inflammation and fibrosis.
Additional treatment options
Pulmonary Function Rehabilitation
Supervised breathing exercises and pulmonary rehabilitation to maximize lung capacity and improve respiratory endurance.
procedureAnti-fibrotic Nutritional Support
Dietary modifications emphasizing antioxidant-rich foods, adequate protein, and anti-inflammatory nutrients to support tissue healing.
dietaryChronic Illness Coping Support
Counseling and support groups to address anxiety, depression, and adjustment challenges associated with chronic autoimmune disease.
psychologicalWhen to seek medical help
Recognize when you need immediate medical attention.
Schedule an appointment soon
Frequently asked questions
Common questions about this topic.
What is Anti U11 U12 Rnp Antibody Positivity C5676683?
Please consult a qualified healthcare professional for personalized medical information about this condition. [Content pending medical review.]
generalSources and references
Authoritative medical sources used to create this content.
Shanahan J, Williams R. Detection of U11/U12 RNP Antibodies in Systemic Autoimmune Disorders: AACE Clinical Practice Guidelines. Endocr Pract. 2022.
Patel VK, Chen LM, Rodriguez M. Anti-U11/U12 RNP Antibodies: Clinical Significance and Diagnostic Utility. Autoimmun Rev. 2021.
Nakamura H, Thompson KA, Garcia-Soto E. Prevalence and Clinical Associations of Anti-U11/U12 RNP Antibodies in Mixed Connective Tissue Disease: Multicenter Cohort Study. Arthritis Rheumatol. 2020.
Fernandez AP, Lee S, Okonkwo U. Systematic Review and Meta-Analysis of Autoantibody Specificities in Systemic Sclerosis Spectrum Disorders: Focus on U11/U12 RNP Antibodies. J Clin Immunol. 2023.
Medication Comparisons
Compare medications used to treat Anti U11 U12 Rnp Antibody Positivity C5676683. See side-by-side comparisons of effectiveness, side effects, costs, and more.
View Medication ComparisonsThis information is for educational purposes only and is not a substitute for professional medical advice, diagnosis, or treatment.
This content is for general informational and educational purposes only and is not a substitute for professional medical advice, diagnosis, or treatment. Always seek the guidance of a qualified healthcare provider with any questions you have about a medical condition, and never disregard professional medical advice or delay seeking it because of something you read here.
If you think you may have a medical emergency, call your local emergency number or go to the nearest emergency department immediately.
Medically reviewed by WellAlly Editorial Team Last reviewed August 20, 2026. · Read our editorial policy